Drug independence

Experts spoke about the practice of using Esperavir® and Skyvir® drugs as etiotropic therapy for COVID–19

The ceremonial opening of a new high-tech tablet production took place at the Biochemist plant of Promomed Group

Quiz: What do you know about the production of medicines?

The drugs Esperavir and Areplivir are included in the current treatment regimens for seasonal acute respiratory viral infections

Promomed DM's long-term creditworthiness rating has been confirmed at giA-, with a stable outlook

With the support of Promomed Group of Companies, special chemistry and mathematics courses have been opened in Saransk schools.

Promomed Group made proposals at the round table "Current approaches to legislative regulation, prevention and treatment of diabetes mellitus" in the State Duma

The revenue of PROMOMED DM LLC for the first 9 months of 2022 increased by 0.75% and amounted to 13.35 billion rubles. Net profit increased by 49.42% to 740.33 million rubles.

Promomed Group of Companies has patented the methods of obtaining and using the drug Radamine® Viro

"Pharma is love": Promomed unites students of Russia's largest universities once again

Promomed Group of Companies has published the first ESG report in its history

Esperavir® is the best launch of 2021 in the budget sales segment according to IQVIA

Phosphazide is a new drug in the Promomed Group's antiretroviral portfolio

From the new academic year, targeted training of specialists for Promomed Group of Companies will start in the three largest universities in the country

Skyvira® is included in the updated list of medicines for the treatment of COVID-19

PROMOMED DM LLC has successfully placed the third issue of exchange-traded bonds worth 2.5 billion rubles

The head of Rospatent, Yuri Zubov, visited the Biochemist plant of Promomed Group of Companies

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office